US2010303815A1PendingUtilityA1
METHOD OF TREATING ANEMIA BY ADMINISTERING IL 1ra
Est. expiryOct 31, 2020(expired)· nominal 20-yr term from priority
A61P 43/00A61P 7/06A61P 7/00A61P 29/00A61P 13/12A61P 19/02C07K 2319/30A61K 38/1816A61K 9/0019A61K 47/54A61K 38/1793A61K 47/55A61K 38/20A61K 33/26A61K 47/26A61K 39/395Y02A50/30
42
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.
Claims
exact text as granted — not AI-modified1 . A method of treating anemia in a mammal, comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an anti-IL-1 receptor antibody.
2 . The method of claim 1 , wherein the treating of anemia raises the hematocrit in the mammal.
3 . The method of claim 2 , wherein the target hematocrit is at least about 30%.
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . The method of claim 2 wherein the mammal suffers from anemia associated with a decline or loss of kidney function.
15 . The method of claim 2 , wherein the mammal suffers from anemia associated with rheumatoid arthritis.
16 . The method of claim 2 , wherein the mammal suffers from anemia associated with myelosuppressive therapy.
17 . The method of claim 16 , wherein the myelosuppressive therapy comprises chemotherapeutic or anti-viral drugs.
18 . The method of claim 2 , wherein the mammal suffers from anemia associated with excessive blood loss.
19 . The method of claim 2 , further comprising administering a therapeutically effective amount of iron.
20 . The method of claim 2 , further comprising administering to the mammal a therapeutically effective amount of an erythropoietin (EPO) receptor agonist.
21 . (canceled)
22 . (canceled)
23 . The method of claim 20 , wherein the anti-IL-1 receptor antibody and the EPO receptor agonist are administered in separate compositions.
24 . The method of claim 20 , wherein the anti-IL-1 receptor antibody and the EPO receptor agonist are administered in separate compositions at different times.
25 . The method of claim 20 , wherein the anti-IL-1 receptor antibody and the EPO receptor agonist are administered in separate compositions at the same time.
26 . The method of claim 20 , wherein the anti-IL-1 receptor antibody and the EPO receptor agonist are administered in the same composition.
27 . (canceled)
28 . (canceled)
29 . The method of claim 20 , wherein the EPO receptor agonist is epoietin alfa.
30 . The method of claim 20 , wherein the EPO receptor agonist is darbepoietin alfa.
31 . (canceled)
32 . (canceled)
33 . (canceled)
34 . The method of claim 20 , wherein the blood disorder treated is anemia of chronic disease.
35 . (canceled)
36 . (canceled)
37 . (canceled)
38 . (canceled)
39 . (canceled)
40 . A composition comprising an anti-IL-1 receptor antibody and an EPO receptor agonist.
41 . (canceled)
42 . (canceled)
43 . The composition of claim 39 , wherein the EPO receptor agonist is darbepoietin alfa.
44 . (canceled)
45 . (canceled)
46 . (canceled)
47 . (canceled)
48 . (canceled)
49 . (canceled)
50 . (canceled)
51 . (canceled)
52 . (canceled)
53 . (canceled)
54 . (canceled)
55 . (canceled)
56 . (canceled)
57 . (canceled)
58 . (canceled)
59 . (canceled)
60 . (canceled)
61 . (canceled)
62 . (canceled)
63 . (canceled)
64 . (canceled)
65 . (canceled)
66 . (canceled)
67 . (canceled)
68 . (canceled)
69 . (canceled)
70 . (canceled)
71 . (canceled)
72 . (canceled)
73 . (canceled)
74 . (canceled)
75 . (canceled)
76 . (canceled)
77 . (canceled)
78 . (canceled)
79 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.